COMMUNICABLE DISEASES

Transcription

1 MIP/2003/FIN/CDS ENGLISH ONLY WORLD HEALTH ORGANIZATION COMMUNICABLE DISEASES INTERIM FINANCIAL STATUS REPORT FOR THE YEAR 2002 FINANCIAL PERIOD COVERING THE PERIOD 1 JANUARY DECEMBER 2002 Incorporating the former Communicable Diseases Cluster excludes HIV/AIDS. From 2004, workplans and s will reflect the Communicable Diseases (CDS) Cluster and the HIV/AIDS, Tuberculosis and Malaria (HTM) Cluster OCTOBER 2003

2 Contents Financial tables Table 1 CDS operating for Table 2 Summary financial status for the year Table 3 and Fig. 1 CDS operating compared with funds available and expenditures, all sources of funds by Area of Work 5 Table 4 Contributions and other income received in Notes 8 This report captures all income contributed by donors to the Communicable Diseases (CDS) at Headquarters in Geneva. Expenditure (which may be on activities in Geneva or in regions and countries) excludes funds transferred by CDS to regional offices. 2.

3 Table 1: CDS operating for as at 31 December Regular WHO Programme Budget (PB): regular Regular by Area of Work and other components Other sources operating Communicable disease surveillance 8,928 8,438 Communicable disease prevention, eradication and control 12,484 6,367 Research and product development for communicable diseases 3,772 2,811 Malaria 4,526 6,291 Tuberculosis 1,131 2,665 Executive Director/ management support unit 4,269 Regular ,841 30,841 (Reference WHO PPB/02-03) Net ary adjustments (Note 1) (1824) Operational regular (Reference WHO Unaudited Interim Financial Report for 2002, Table 3) 2. Other sources and adjustments to form operating Other sources (Note 2) Total other sources operating Operating broken down by Area of Work, EXD (Reference Table 3) Total Regular Other sources Communicable disease surveillance Communicable disease prevention, eradication and control Research and product development for communicable diseases Malaria Tuberculosis Executive Director/management support unit Total operating (Note 3)

4 Table 2: CDS summary financial status for the year 2002 as at 31 December 2002 Breakdown by source of funds Regular Other sources Total Operating Opening balance 1 January 2002 ( Note 4) a Income b (Reference Table 4) Total funds a + b=c Transfers To regions and clusters (Note 5) 0 (67 819) (67 819) Total transfers d 0 (67 819) (67 819) Funds available at headquarters (operating income) c - d=e ( Note 6) Expenditures f (Reference WHO Unaudited Interim Financial Report for 2002, Table 3) Balance available at headquarters at 31 December 2002 e - f=g Interest accrued in 2002 for use in h Balance of funds transferred by headquarters to regions or clusters at 31 December 2002 j Closing balance 31 December 2002 (Note 7) k=g + h + j

5 Table 3: CDS operating compared with funds available and expenditures, all sources of funds by Area of Work as at 31 December 2002 Implementation rates Income received in Cluster 2002 net of transfers operating to regional offices and clusters Funds available Expenditures Expenditure/ Expenditure/ funds available Communicable disease surveillance (CSR) % 59% Communicable disease prevention, eradication and control (CPE) % 48% Research and product development for communicable diseases (TDR) % 64% Malaria (MAL) (8 848) % 66% Tuberculosis (STB) % 81% Executive Director/management support unit (EXD/MSU) % 41% Total % 62% Reference Table 1 Table 2 Table 2 Figure 1: CDS operating, funds available and expenditures 120, ,000 80,000 operating funds available expenditures 60,000 40,000 20,000 0 CSR CPE TDR RBM STB EXD/MSU 5.

6 Table 4: CDS Contributions and other income received in 2002 Contributions to the Voluntary Fund for Health Promotion & TDR Trust Fund as at 31 December Unspecified Specified Total Firm pledges Donor countries Australia 867, ,537 1,357,730 0 Belgium 368, ,970 1,281,665 0 Canada 0 10,958,221 10,958,221 0 Cyprus 0 20,000 20,000 0 Denmark 0 1,984,127 1,984,127 0 France 0 2,431,344 2,431,344 25,543 Germany 1,253,893 1,097,405 2,351, ,326 Greece 0 20,000 20,000 India 0 25,000 25,000 0 Ireland 83, , , ,922 Italy 795,075 3,182,702 3,977,777 0 Japan 770,000 2,125,000 2,895,000 0 Kuwait 0 20,000 20,000 0 Lebanon 0 61,642 61,642 0 Luxembourg 758, ,968 1,677,091 0 Malaysia 0 25,000 25,000 0 Netherlands 3,898,983 4,339,180 8,238,163 6,537,217 New Zealand 0 42,930 42,930 0 Norway 2,268,292 3,433,838 5,702,130 Republic of Korea 10, , , ,250 Spain 16,598 75,647 92,245 0 Sweden 0 2,510,186 2,510,186 0 Switzerland 33, , , ,892 Syria 0 60,000 60,000 0 Thailand 0 35,768 35,768 0 Turkey 0 25,000 25,000 0 United Kingdom 2,081,250 21,942,433 24,023, ,256 United States of America 32,770 14,129,930 14,162,700 19,525,701 Miscellaneous (below US $20,000) 0 46,571 46,571 0 sub-total, donor countries 13,237,912 72,504,641 85,742,553 27,749,107 % of category 15% 85% 100% UN organizations and agencies Joint United Nations Programme on HIV/AIDS 0 448, ,630 0 United Nations Children's Fund 0 150, ,000 0 United Nations Development Programme 24, ,977 0 United Nations Fund for International Partnerships ,503,500 World Bank 0 3,295,300 3,295,300 0 World Bank (Bill & Melinda Gates Foundation) 0 3,600,000 3,600,000 0 sub-total, UN organizations and agencies 24,977 7,493,930 7,518,907 1,503,500 % of category 0.33% 99.66% 100% Other contributors African Programme For Onchocerciasis Control, Burkina Faso 0 1,620,000 1,620,000 0 Arab Gulf Programme for UN Development Organizations ,000 Aventis Environmental Science SA, France 12, ,000 0 Aventis Pasteur SA, France 5, ,000 0 Aventis Pharma, Deutschland GMBH, Germany 0 2,470,127 2,470,127 0 BASF Corp., USA 4, ,500 0 Bayer AG., Germany 17, ,979 0 Bill & Melinda Gates Foundation 0 4,425,000 4,425,000 4,500,000 Bristol Meyers Squibb, USA 0 400, ,000 0 CIBC World Markets Corporation, USA 2,700 2,700 0 City of Lyon, France 0 274, , ,926 6.

7 Commission of the European Communities 0 137, ,660 0 Crompton Europe B.V., Netherlands 10, ,000 0 EURO Health Group A/S, Denmark 0 39,723 39,723 0 FMC Corporation, USA 4, ,500 0 Fondation Follereau, France 31, ,697 0 Fondation Mérieux, France 0 1,441,446 1,441,446 0 Fundacion Anesvad, Spain 105, ,000 0 Glaxo SmithKline, UK 51, , ,000 0 Global Forum for Health Research, Switzerland 0 250, ,000 0 Health Research Inc., USA 16, ,200 0 Infectious Disease Research Institute, USA 0 200, ,000 0 International Development Research Centre, Canada 0 16,890 16,890 0 International Federation of Pharmaceutical Manufacturers Associations 0 50,000 50,000 0 Liverpool School of Tropical Medicine, UK 14, ,822 0 London School of Hygiene & Tropical Medicine, UK 0 773, ,438 0 Makhteshim Chemical Works Ltd., Israel 14, ,975 0 Medicines for Malaria Venture, Switzerland 0 1,138,363 1,138,363 0 Merck & Co Inc., USA 25, ,000 0 New York Community Trust, USA 0 50,000 50,000 0 Nippon Foundation, Japan 0 600, ,000 0 Novartis Foundation, Switzerland 25, , ,353 0 Nuclear Threat Initiative, USA 0 500, ,000 0 Onchocerciasis Control Programme, Burkina Faso 0 225, ,000 0 Open Society Institute, USA 0 219, ,500 0 Procter & Gamble AG, Switzerland 0 46,940 46,940 0 Research Institute of Tuberculosis, Japan 14, ,040 0 Rockefeller Foundation 13, , ,340 0 Sasakawa Health Trust Fund 0 4,865,000 4,865,000 0 Sumito Chemical Company Ltd, Japan 75, ,800 0 The Task Force for Child Survival & Development 9, ,183 0 TIFA (C.I.) Limited, USA 15, ,000 0 University Hospital of North Norway 0 25,425 25,425 0 University of Harvard, USA 0 438, ,124 0 Valent Biosciences Corp. 42, ,000 0 Vestergaard Frandsen A/S, Denmark 42, ,000 0 Wellcome Trust, UK 0 29,000 29,000 0 Zenryokyo Fund, Japan 22, ,375 0 Miscellaneous 106, , ,542 0 Administrative support funds(as) 0 2,944,011 2,944,011 0 Sub-total, other contributions 680,828 25,387,442 26,068,270 5,145,926 % of category 3% 97% 100% Total income prior to adjustment 13,943, ,386, ,329,730 34,398,533 % of category 12% 88% 100% Adjustments, refunds and rebates 0-595, ,162 0 Total Other Sources 13,943, ,790, ,734,568 34,398,533 % of category 12% 88% 100% WHO Regular 0 29,017,668 29,017,668 0 Sub.total WHO contribution 0 29,017,668 29,017,668 0 % of category 0% 100% 100% Total income 13,943, ,808, ,752,236 34,398,533 % of category 9% 91% 100% 7.

8 Notes 1. Net ary adjustments include reductions in the regular made centrally to reflect corporate efficiency savings and changes in exchange rates. 2. The other sources operating reflects the cost of planned activities within the areas of work in CDS. 3. These figures correspond to the areas of work in CDS in the programme. 4. This represents the opening balance at Headquarters plus unexpended balance at Regional Offices as of 1 January Transfers to regions amounted to US$ 67.8 million of which more than 50% were transferred to the Regional Office of Africa. 6. Funds available at Headquarters for programme implementation after transfers to the regions. 7. This is the sum total of balance available on 31 December 2002 at Headquarters and in the regions including accrued interest. 8.